HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

13,56

24-января-25 16:45:00

15 мин. задержка

Акции

-0,04

-0,29%

Сегодняшний диапазон

13,39 - 13,61

ISIN

N/A

Источник

NASDAQ

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

13 янв 2025 23:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

01 янв 2025 19:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

01 янв 2025 05:46:43 Источник Nasdaq GlobeNewswire
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

12 дек 2024 19:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

11 дек 2024 23:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

03 дек 2024 05:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

28 ноя 2024 05:30:00 Источник Nasdaq GlobeNewswire
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

21 ноя 2024 23:30:00 Источник Nasdaq GlobeNewswire
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

20 ноя 2024 04:30:00 Источник Nasdaq GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

05 ноя 2024 23:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

31 окт 2024 04:30:00 Источник Nasdaq GlobeNewswire
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

16 окт 2024 00:30:00 Источник Nasdaq GlobeNewswire
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

24 сен 2024 03:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

08 сен 2024 20:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

30 авг 2024 00:30:00 Источник Nasdaq GlobeNewswire
HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

21 авг 2024 04:30:00 Источник Nasdaq GlobeNewswire
HUTCHMED Reports 2024 Interim Results and Provides Business Updates

31 июл 2024 07:00:01 Источник Nasdaq GlobeNewswire
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

03 июл 2024 20:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED to Announce 2024 Half-Year Financial Results

26 июн 2024 04:30:00 Источник Nasdaq GlobeNewswire
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

24 июн 2024 05:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.